SFDA
In Sluggish World Economy, Array Companies Encouraged by China's Fast Growing Clinical Market
Premium
"Explosive" and "enormous" are the words Simon Sheng uses to describe the market for microarray technology in China. As general manager for Affymetrix's office in the country, Sheng said he has hired eight sales and marketing personnel this year and hopes to add more soon.
Is Healthlinx Eyeing Purchase of Correlogic's Assets as Part of Move into US Cancer Dx Market?
Premium
This story originally ran on Oct. 12.
By Adam Bonislawski
BGI, which, according to an official, generated roughly $6.2 million in proteomics revenue last year, plans to buy around 15 new high-resolution machines and 30 to 40 triple quadrupoles as part of its efforts to expand into the clinical proteomics and pharma markets.